{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:01:39Z","timestamp":1765609299558},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T00:00:00Z","timestamp":1121731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Fibroblast Growth Factor (FGF) 23 has been shown to play important roles in the development of hypophosphatemic rickets\/osteomalacia. Complementary DNA predicts that the FGF23 protein is composed of 251 amino acids and N\u2010terminal 24 amino acids seem to be a signal peptide. In vitro experiments indicate that a part of the FGF23 protein is processed between arginine179 and serine180. When full\u2010length, N\u2010terminal and C\u2010terminal processed fragments of FGF23 were injected into mice, only the full\u2010length FGF23 reduced serum phosphate levels indicating that the processing of FGF23 abolished its effect to cause hypophosphatemia. This processing was shown to be prevented by an inhibitor of furin indicating that the cleavage is mediated by subtilisin\u2010like proprotein convertase. In addition to this processing, FGF23 protein seems to have O\u2010linked glycosylation. Further studies are necessary to clarify the importance of O\u2010glycosylation for FGF23 activity.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2005.00289.x","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T01:26:10Z","timestamp":1121822770000},"page":"319-322","source":"Crossref","is-referenced-by-count":29,"title":["Post\u2010translational Modification of Fibroblast Growth Factor 23"],"prefix":"10.1111","volume":"9","author":[{"given":"Seiji","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/366575a0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/81664"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.101545198"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021105"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020881"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419081"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-130"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.134.3.549"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119276"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115735"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.1.11"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5084"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.4.E837"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304544200"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.04.002"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/endo.143.8.8795","article-title":"Mutant FGF\u201023 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo","volume":"143","author":"Shimada T","year":"2001","journal-title":"Endocrinology"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00064.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-1-88"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1358"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mop.0000133636.56790.4a"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi034"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2005.00289.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2005.00289.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:31:24Z","timestamp":1697056284000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2005.00289.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1744-9987.2005.00289.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2005.00289.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,19]]}}}